Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era - real-world data from Hungary
Autologous stem cell transplantation (ASCT) is the standard treatment of primary refractory or relapsed Hodgkin-lymphoma, which can provide a cure rate of about 50%. The aim of our study was to analyze the data of 126 HL patients undergoing AHSCT in Hungary between 01/01/2016 and 31/12/2020. We asse...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2023
|
| Sorozat: | ANNALS OF HEMATOLOGY
102 No. 9 |
| Tárgyszavak: | |
| doi: | 10.1007/s00277-023-05354-8 |
| mtmt: | 34067943 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/28123 |
| LEADER | 02420nab a2200325 i 4500 | ||
|---|---|---|---|
| 001 | publ28123 | ||
| 005 | 20230829085312.0 | ||
| 008 | 230829s2023 hu o 0|| Angol d | ||
| 022 | |a 0939-5555 | ||
| 024 | 7 | |a 10.1007/s00277-023-05354-8 |2 doi | |
| 024 | 7 | |a 34067943 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 1 | |a Husi Kata | |
| 245 | 1 | 0 | |a Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era - real-world data from Hungary |h [elektronikus dokumentum] / |c Husi Kata |
| 260 | |c 2023 | ||
| 300 | |a 2555-2563 | ||
| 490 | 0 | |a ANNALS OF HEMATOLOGY |v 102 No. 9 | |
| 520 | 3 | |a Autologous stem cell transplantation (ASCT) is the standard treatment of primary refractory or relapsed Hodgkin-lymphoma, which can provide a cure rate of about 50%. The aim of our study was to analyze the data of 126 HL patients undergoing AHSCT in Hungary between 01/01/2016 and 31/12/2020. We assessed the progression-free and overall survival, the prognostic role of PET/CT performed before transplantation and effect of brentuximab vedotin (BV) treatment on survival outcomes. The median follow-up time from AHSCT was 39 (1-76) months. The 5-year OS comparing PET- and PET + patients was 90% v. 74% (p = 0.039), and 5-year PFS was 74% v. 40% (p = 0.001). There was no difference in either OS or PFS compared to those who did not receive BV before AHSCT. We compared BV treatments based on their indication (BV only after AHSCT as maintenance therapy, BV before and after AHSCT as maintenance treatment, BV only before AHSCT, no BV treatment). There was statistically significant difference in the 5-year PFS based on the inication of BV therapy. Recovery rates of our R/R HL patient population, who underwent AHSCT, improved significantly. Our positive results can be attributed to the PET/CT directed, response-adapted treatment approach, and the widespread use of BV. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Szabó Roxána |e aut |
| 700 | 0 | 1 | |a Pinczés László Imre |e aut |
| 700 | 0 | 1 | |a Földeák Dóra Melinda |e aut |
| 700 | 0 | 1 | |a Dudley Réka |e aut |
| 700 | 0 | 1 | |a Szomor Árpád |e aut |
| 700 | 0 | 1 | |a Koller Beáta |e aut |
| 700 | 0 | 1 | |a Gopcsa László |e aut |
| 700 | 0 | 1 | |a Illés Árpád |e aut |
| 700 | 0 | 1 | |a Miltényi Zsófia |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/28123/1/Foldeak.pdf |z Dokumentum-elérés |